![{[setting('site_name')]}](https://swipenews.ca/uploads/setting/17099612221434575116.webp)
The mRNA vaccine, known as BTN116, developed by the German biotechnology company BioNTech, is the first of its kind and has entered phase 1 clinical trials in seven countries. This new approach aims to harness the precision of mRNA to target and fight lung cancer cells, potentially offering a significant advancement in cancer treatment. The trials mark a promising development in personalized medicine and immunotherapy.
